Key Takeaways
- Revenue fell 12% YoY, but gross margin improved QoQ: supply disruptions, partner inventory rationalization and softer new-product offtake drove the top-line decline, while a favorable geography and product mix lifted gross margin sequentially.
- The inventory destocking hit harder than expected: partners cut inventory from 7–8 months to lower levels, and the B2B nature of Gland’s business amplified the impact across most products, not just one. End-market share on key products remains intact.
- Competitor exits are a near-term pain, long-term gain: several players are leaving the space due to price and cost pressure, creating a temporary revenue drag on products Gland supplies to them, but management expects reduced competition to support pricing once shortages emerge.
- Cenexi acquisition is the strategic offset to generics pressure: the deal, expected to close by March–April 2023, shifts the mix toward CDMO revenue and dilutes the competitive intensity Gland faces in the pure generics space.
- What to watch next quarter: whether the stopper second-source approval arrives and unlocks Heparin shipments, the pace at which product transfers from FDA-hit competitors convert into orders, and any early revenue contribution from the first China approval.
Revenue Headwinds: Supply, Inventory & Competition
- Production disruptions: a two-week shutdown at the Pashamylaram plant for line upgradation and a still-ramping insulin line constrained output during the quarter.
- Supply chain: most issues are resolved, but a few persist, notably the wait for a second-source Heparin stopper approval. A CBE30 was submitted this month and approval is expected in the next month or two.
- Inventory rationalization: partners reduced inventory from 7–8 months to lower levels due to high fed rates, and the B2B model meant Gland absorbed a larger impact than other players. The offtake softness was visible across most products, not isolated to one.
- New product launches underwhelmed: five SKUs shipped, including Regadenoson and Lacosamide, but launches overall did not perform well due to market competition.
- Competitive exits: several companies are exiting certain products and businesses because price pressures and costs have made them unviable. Gland supplies some of these players, so their exit creates a near-term revenue headwind, but management views it as a long-term positive as competition reduces and prices catch up when products go into shortage.
Srinivas Sadu: "We are seeing that, as we speak, some players exiting the space. It is that the temporary blip where we are also supplying products to these companies, but when they exit, there will be a revenue pressure. But then it's also in long term, it's good because the competition is getting reduced."
Margin Strategy: Protect Price, Improve Internally
- Gross margin improved QoQ: the uplift came from qualifying alternative, cheaper material sources that increased contribution margin on some products, larger batch sizes for better efficiencies, and a mix shift away from lower-margin products toward higher-margin ones.
- EBITDA declined 11% YoY: higher employee costs from staffing new production lines at Pashamylaram and the Bio-CDMO facility, plus elevated energy costs (though lower than Q2 FY23), more than offset the gross margin gain.
- Management is reluctant to buy revenue with price cuts: the explicit strategy is to keep margins intact and improve them internally rather than compromise on price for aggressive top-line growth, which management calls "permanent damage" to the market.
- Profit share sustainability: the 9% profit share level is expected to be sustainable.
- Margin focus for coming quarters: qualifying alternate, cheaper material sources and minimizing low-margin products to free capacity for high-margin products.
Srinivas Sadu: "One way is do we want to compromise on your margin and then go aggressively on the top line and which we are reluctant to do because then it's a permanent damage you're going to cause for the market."
Product-Specific Dynamics
- Heparin: Gland dispatched whatever supply it received; the next supply is not in the near term. The 30 mL contract is still held and orders and forecasts are in place. High-value inventory is sitting at Gland, with API and other components ready, waiting only for the stopper.
- Enoxaparin: revenue is lumpy quarter-to-quarter due to billing timing and partner NDC transitions; the annual run rate is approximately $50 million, with an aspiration to reach $70–80 million as the NDC transition progresses, though no timeline was given.
- Micafungin: was a large product in 2021 at INR 300–400 crores; that situation has now settled. Market share is still at 50% versus 80% in the first year, and no further downside is expected.
- Stopper supply: described as a "once in a lifetime" situation driven by COVID-era diversion to vaccine production; a second supplier has been qualified and a CBE30 submitted, with approval expected in the next month or two.
Srinivas Sadu: "Stopper manufacturing and glass manufacturing is not our area of expertise, so we can't really manufacture those. And at the scale at which these are manufactured overall, this is like a situation once in a lifetime."
Growth Levers: Transfers, China & Capacity
- Product transfers from FDA-hit competitors: Gland is actively interacting with two companies that received import alerts or warning letters to transfer some products to Gland sites. Several products are under discussion, some at the agreement stage, and transfers could become a positive contributor from Q1 of the next fiscal year.
- One biologics line converted back: to cater to increased demand from transfer opportunities, one biologics line was converted to the regular product portfolio and is being added this quarter.
- China approvals: a couple of products filed in China are in advanced stages of regulatory review; one product with a ~$100 million market is expected to receive clearance anytime, possibly in January, February, or next quarter. Gland is targeting 14 products until this year, with a few more next year, including several billion-dollar products.
- Pashamylaram ramp-up: first exhibit batches are being taken; one line is to be commercialized this quarter, two more next quarter. When fully qualified and commissioned, the site will have 11 lines.
- Complex injectables: four complex products have been filed so far (two last year, two this quarter), with one or two expected to receive approvals in FY24.
- Cenexi acquisition: expected to close by March–April 2023; 100% of Cenexi’s revenue comes from CDMO, which management says will improve Gland’s mix by diluting the competitive intensity of the generics space.
Srinivas Sadu: "With Cenexi acquisition where the entire 100% of the revenue comes from the CDMOs, our mix actually improves because the competition what we're seeing in the generic space will get diluted a bit because we are more stronger CDMO players in that sense."
Working Capital & Balance Sheet
- Cash conversion cycle stretched to 246 days from 190 days, driven by higher inventory and receivable levels.
- Receivables spike: most sales occurred toward quarter-end and receivables were not yet due, a pattern similar to the last two quarters; the prior year had more uniform sales. The ROW business also contributed to the receivables increase.
- Inventory buildup at Gland: long lead times, lower offtake (though end-market demand is intact), and preparation for opportunities from FDA issues at other sites all contributed. The Heparin situation is a clear example: API and other components are held in inventory, waiting for one missing stopper.
- Cash utilization: ₹3,829.7 crore of cash is intended for the capex plan and to fund the Cenexi acquisition.
- Overall capex: INR 200–250 crores for FY23, INR 300 crores for FY24, excluding biosimilars.
- R&D spend: already at the highest end versus historical levels at ~5–5.5% of revenue; no significant increase is expected as this level is already baked in.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Cenexi acquisition close | Deal closure expected | March–April 2023 |
| Stopper second-source approval | CBE30 submitted; approval expected | Next month or two |
| China first product approval | One product (~$100M market) in advanced review | Anytime: Jan, Feb, or next quarter |
| Product transfers from FDA-hit competitors | Several products under discussion, some at agreement stage; positive contribution expected | Q1 FY24 |
| Pashamylaram line commercialization | One line this quarter, two more next quarter | Current quarter and next quarter |
| Complex injectable approvals | One or two products expected to receive approvals | FY24 |
| Cash conversion cycle normalization | Increased receivable and inventory days expected to normalize | No specific date; expectation stated |
| Gross margin | Maintain current level | Ongoing; market-dependent |
| R&D spend | Remain at ~5–5.5% of revenue, no significant increase | Ongoing |
| Overall growth recovery | Growth expected to come back | Fiscal 2024 (estimate) |
Key Metrics
| Metric | Q3 FY23 |
|---|---|
| Revenue from operations | ₹938.3 cr, down 12% YoY |
| Revenue from operations (9M FY23) | ₹2,839.6 cr, down 14% YoY |
| Gross margin | Improved QoQ due to geography and product mix; 9M stable YoY |
| EBITDA | ₹351.1 cr, down 11% YoY |
| EBITDA margin (excl. other income) | 31% for Q3, 30% for 9M FY23 |
| Net profit (PAT) | ₹231.9 cr, down 15% YoY |
| PAT margin | 23% for Q3 and 9M FY23 |
| Other income | ₹61.5 cr, includes interest on fixed deposits and forex gains |
| R&D expenditure (total) | ₹51.2 cr, 5.5% of revenue vs 6.6% in Q3 FY22 |
| R&D expenditure (excl. capital R&D) | ₹50 cr, 5.3% of revenue vs ₹39.4 cr in Q2 FY23 |
| Effective tax rate | ~25% for Q3, 26% for 9M FY23 |
| Cash flow from operations (Q3) | ₹39.8 cr |
| Cash flow from operations (9M FY23) | ₹435.4 cr |
| Cash and bank balances | ₹3,829.7 cr as of Dec 2022 |
| Total capex incurred (9M FY23) | ₹125.3 cr |
| Capex guidance | ₹200–250 cr for FY23, ₹300 cr for FY24 |
| Working capital | ₹2,332.2 cr as of Dec 2022, up from ₹2,021.7 cr in Mar 2022 |
| Average cash conversion cycle | 246 days for 9M ending Dec 2022 vs 190 days in same period last year |
| ROCE (ex-cash, annualized) | 20% for 9M FY23 |
| Fixed assets turnover | 2.4x for 9M FY23 vs 3.2x in same period last year |
| Profit share | 9% of revenue vs 7% in Q2 FY23 and 10% in Q3 FY22 |
| Core markets revenue share | 70% of Q3 revenue, similar to Q3 FY22 |
| Rest-of-the-world markets revenue share | 21% of Q3 revenue vs 19% in Q3 FY22 |
| India market revenue share | 9% of Q3 revenue |
| ANDA filings completed in Q3 | 8 filings |
| Cumulative ANDA filings in the US | 325 as of Dec 2022, along with partners |
| Cumulative product registrations globally | 1,581 as of Dec 2022, along with partners |
| Enoxaparin annual revenue run rate (US) | ~$50 million; Q3 FY23 was ~$5 million due to timing |
| Complex injectable products filed | 4 total, combined market value ~₹200 cr |
| Biosimilar CDMO capex spent to date | ~₹300 cr |
| Pashamylaram plant lines | 8 currently, 3 under validation; expanding to 11 total |
| China product opportunity | One product near approval with market size of ~$100 million |